Search

Displaying results 571 - 580 of 9682 in total
  1. Drug

    Azacitidine

    go.drugbank.com/drugs/DB00928
    ApprovedInvestigational

    Azacitidine is a pyrimidine nucleoside analogue with anti-neoplastic activity. It differs from cytosine by the presence of nitrogen in the C5-position, key in its hypomethylating activity.

  2. Drug

    Datopotamab deruxtecan

    go.drugbank.com/drugs/DB16410
    ApprovedInvestigational

    Datopotamab deruxtecan is an antibody-drug conjugate comprising a Trop-2-directed monoclonal antibody (datopotamab) and a DNA topoisomerase-I inhibitor, DDx.

  3. Drug

    Digoxin

    go.drugbank.com/drugs/DB00390
    ApprovedInvestigational

    [A178225] It is a common agent used to manage atrial fibrillation and the symptoms of heart failure. … [A178234] Digoxin is classified as a cardiac glycoside and was initially approved by the FDA in 1954.

    Categories: BSEP/ABCB11 Substrates with a Narrow Therapeutic Index, P-glycoprotein substrates with a Narrow Therapeutic Index
  4. Drug

    CX-052075

    go.drugbank.com/drugs/DB31655
    Approved

    CX-052075 is a nucleoside-modified messenger RNA (mRNA) encoding the N-terminal domain (NTD) and receptor-binding domain (RBD) of the spike glycoprotein of the SARS-CoV-2 Omicron variant sublineage LP.8.1 … [L53408,L53423] The original approval was formulated with the JN.1 strain ([mRNA-1283]), but was ultimately updated to the sublineage LP.8.1.[L54586]

  5. Drug

    Idelalisib

    go.drugbank.com/drugs/DB09054
    ApprovedInvestigational

    Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic … For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination with rituximab in patients for whom rituximab alone would be considered appropriate therapy due to other

    Categories: Class Ia Phosphatidylinositol 3-Kinase, antagonists & inhibitors, P-glycoprotein substrates with a Narrow Therapeutic Index
  6. Drug

    Ibutilide

    go.drugbank.com/drugs/DB00308
    Approved

    Ibutilide is a Class III antiarrhythmic agent available in intravenous formulations.

  7. Drug

    Radium Ra 223 dichloride

    go.drugbank.com/drugs/DB08913
    ApprovedInvestigational

    Radium Ra 223 Dichloride is a radiopharmaceutical containing the radioisotope radium-223 that emits short range but high linear energy alpha particles. … As a cation, radium mimics calicum and binds to hydroxyapatite, which is a bone mineral found in areas of high bone turnover as seen in bone metastases.

    Synonyms: Radium chloride Ra-223, Radium (Ra-223) dichlorideProducts: Radium Ra 223 Dichloride
  8. Drug

    Hydroquinone

    go.drugbank.com/drugs/DB09526
    ApprovedInvestigational

    As a result of these concerns, hydroquinone has been banned in the EU and UK. … Hydroquinone is a topical lightening product found in OTC products, and is used to correct skin discoloration associated with disorders of hyperpigmentation including melasma, post-inflammatory hyperpigmention

    Mixtures: CREMA CON ACIDO GLICOLICO AL 8%Categories: Compounds used in a research, industrial, or household setting
  9. Drug

    SAR-260301

    go.drugbank.com/drugs/DB33608
    Investigational

    Categories: Class Ia Phosphatidylinositol 3-Kinase, antagonists & inhibitors
  10. Drug

    Buspirone

    go.drugbank.com/drugs/DB00490
    ApprovedInvestigational

    Buspirone is a novel anxiolytic agent with a unique structure and a pharmacological profile. … Belonging to the azaspirodecanedione drug class,[A180991] buspirone is a serotonin 5-HT<sub>1A</sub> receptor agonist that is not chemically or pharmacologically related to benzodiazepines, barbiturates